Inovio Pharmaceuticals clinical trials we track

Check company identity source

Phase 3 2 trials

Phase 2 / 3 1 trial

Phase 2 3 trials

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Frequency of Adverse Events in Part 1 Measure: Percentage of Participants with Adverse Events in Part 1 Measure: Frequency of Injection Site Reactions in Part 1 Measure: Percentage of Participants with Injection Site Reactions in Part 1 Measure: Frequency of Adverse Events of Special Interest (AESIs) in Part 1 Measure: Percentage of Participants with Adverse Events of Special Interest (AESIs) in Part 1 Measure: Geometric Mean Titers (GMTs) of MERS-CoV Antigen Specific Binding Antibodies in Part 1 Measure: Percentage MERS-CoV Antigen Specific Neutralizing Antibodies in Part 1 Measure: Percentage Antigen Specific Cellular Immune Response in Part 1 Measure: Percentage of Seroconverted Participants in Part 1 Measure: Percentage of Participants with Overall Immune Response in Part 1 Measure: Frequency of Adverse Events in Part 2 Measure: Percentage of Participants with Adverse Events in Part 2 Measure: Frequency of Injection Site Reactions in Part 2 Measure: Percentage of Participants with Injection Site Reactions in Part 2 Measure: Frequency of Adverse Events of Special Interest (AESIs) in Part 2 Measure: Percentage of Participants with Adverse Events of Special Interest (AESIs) in Part 2 Measure: Geometric Mean Titers (GMTs) of MERS-CoV Antigen Specific Binding Antibodies in Part 2 Measure: Percentage MERS-CoV Antigen Specific Neutralizing Antibodies in Part 2 Measure: Percentage Antigen Specific Cellular Immune Response in Part 2 Measure: Percentage of Seroconverted Participants in Part 2 Measure: Percentage of Participants with Overall Immune Response in Part 2. After: Measure: Part 1: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs), Graded by Severity, and Treatment-related AEs Measure: Part 1: Percentage of Participants With Injection Site Reactions Measure: Part 1: Percentage of Participants With Adverse Events of Special Interest (AESIs) Measure: Part 1: Geometric Mean Concentration (GMC) of INO-4700 Antigen Specific Binding Antibody at Week 6 Measure: Part 1: Geometric Mean Fold Rise (GMFR) of INO-4700 Antigen Specific Binding Antibody at Week 6 Measure: Part 1: Geometric Mean Concentration (GMC) of INO-4700 Antigen Specific Binding Antibody at Week 10 Measure: Part 1: Geometric Mean Fold Rise (GMFR) of INO-4700 Antigen Specific Binding Antibody at Week 10 Measure: Part 1: Percentage Neutralizing Antibody Responders at Week 6 Measure: Part 1: Percentage Neutralizing Antibody Responders at Week 10 Measure: Part 1: Percentage of Antigen Specific Cellular Immune Responders at Week 6 Measure: Part 1: Percentage of Antigen Specific Cellular Immune Responders at Week 10 Measure: Part 2: Percentage of Participants With Adverse Events Measure: Part 2: Percentage of Participants With Injection Site Reactions Measure: Part 2: Percentage of Participants With Adverse Events of Special Interest (AESIs) Measure: Part 2: Geometric Mean Concentration (GMC) of INO-4700 Antigen Specific Binding Antibody Measure: Part 2: Percentage Neutralizing Antibody Responders Measure: Part 2: Percentage of Antigen Specific Cellular Immune Responders.

Check registry source